UFIS-SWE-IG
0.1.0 - ci-build
UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions
Generated Narrative: MedicinalProductDefinition EMLA-2525-Plaster-SE-AJ-MPD
identifier: http://ema.europa.eu/fhir/mpId
/SE-100001718-00011834, http://ema.europa.eu/fhir/eurdId
/1867
domain: Human use
status: Current
combinedPharmaceuticalDoseForm: Medicated plaster
indication:
Emla plåster används vid: • Ytanestesi av intakt hud i samband med: o nålstick, t.ex. vid inläggning av perifer venkateter eller vid blodprovstagning o ytliga kirurgiska ingrepp, hos vuxna och den pediatriska populationen
legalStatusOfSupply: Medicinal product subject to medical prescription exempt for some pack sizes
classification: combinations
name
productName: EMLA 25 mg/25 mg Medicinskt plåster
part
part: EMLA
type: Invented Name Part
part
part: 25 mg/25 mg
type: Strength part
part
part: Medicinskt plåster
type: Pharmaceutical dose form part
Usages
Country Language Kingdom of Sweden Swedish